Cefdinir
Cefdinir, sold under the brand name Omnicef among others, is an antibiotic used to treat pneumonia, otitis media, strep throat, and cellulitis. It is a less preferred option for pneumonia, otitis media, and strep throat which may be used in those with a severe allergy to penicillin. It is taken by mouth.
Clinical data | |
---|---|
Pronunciation | SEF-di-nir |
Trade names | Cefzon, Omnicef, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a698001 |
License data | |
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 16% to 21% (dose-dependent) |
Protein binding | 60% to 70% |
Metabolism | Negligible |
Elimination half-life | 1.7 ± 0.6 hours |
Excretion | Kidney |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.171.145 |
Chemical and physical data | |
Formula | C14H13N5O5S2 |
Molar mass | 395.41 g·mol−1 |
3D model (JSmol) | |
Melting point | 170 °C (338 °F) (dec.) |
SMILES
| |
| |
(verify) |
Common side effects include diarrhea, nausea, and a skin rash. Serious side effects may include Clostridioides difficile infection, anaphylaxis, and Stevens–Johnson syndrome. Use in pregnancy and breastfeeding is believed to be safe but has not been well studied. It is a third-generation cephalosporin and works by interfering with a bacteria's ability to make a cell wall resulting in its death.
It was patented in 1979 and approved for medical use in 1991. It is available as a generic medication. In 2021, it was the 197th most commonly prescribed medication in the United States, with more than 2 million prescriptions.